drugset / Trial / NCT01779869
Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson
Phase 4
Completed
16 enrolled
Washington University School of Medicine
Astellas Pharma US, Inc. · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The objective for this pilot study is to develop an optimized, clinically usable myocardial PET-MR perfusion protocol and to determine which of all data potentially available should be acquired for a clinical myocardial perfusion examination. Hypothesis: The hypothesis is that high resolution, high sensitivity DCE MRI could replace the rest PET myocardial perfusion imaging, significantly decreasing examination time and patient radiation dose while maintaining the comprehensive reference-quality PET myocardial stress perfusion coverage. The primary outcome will be comparison of diagnostic accuracy of each combination of imaging to detect clinically significant coronary artery stenosis (≥70% diameter stenosis).
Timeline
- Start
- 2013-01
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Regadenoson | Diagnostic / imaging agent | 400 ug | Intravenous |